Citius Pharmaceuticals
CTXR
76 hedge funds and large institutions have $37.5M invested in Citius Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 8 closing their positions.
151% more call options, than puts
Call options by funds: $801K | Put options by funds: $319K
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
7% more funds holding
Funds holding: 71 → 76 (+5)
0.02% less ownership
Funds ownership: 0.69% → 0.67% (-0.02%)
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
27% less capital invested
Capital invested by funds: $51.1M → $37.5M (-$13.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$723K |
| 2 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
+$312K |
| 3 |
Barclays
London,
United Kingdom
|
+$166K |
| 4 |
HF
HRT Financial
New York
|
+$165K |
| 5 |
AGM
Alpine Global Management
New York
|
+$151K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.8M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$1.06M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$351K |
| 4 |
Goldman Sachs
New York
|
-$252K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$149K |
CTXR Hedge Fund Activity: Q4 2021 in Review
76 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q4 2021, worth a combined $37.5M — down 27% from $51.1M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CTXR positions and 8 closed out — a net gain of 7 holders — while 22 added to existing stakes and 23 trimmed.
The largest buyer was Vanguard Group, adding an estimated $723K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.8M sold.
- 76 institutional investors held Citius Pharmaceuticals (CTXR) as of Q4 2021, up from 71 in Q3 2021.
- Funds reported $37.5M of Citius Pharmaceuticals stock for Q4 2021, down 27% quarter-over-quarter.
- 15 funds opened new Citius Pharmaceuticals positions in Q4 2021 and 8 closed out, a net change of +7 holders.
- The largest Citius Pharmaceuticals buyer in Q4 2021 was Vanguard Group, an estimated $723K added.
- The largest Citius Pharmaceuticals seller in Q4 2021 was Renaissance Technologies, an estimated $1.8M sold.
Based on aggregated 13F filings for Q4 2021.